ACCEL Lite: Statins To Prevent The Cardiotoxicity From Anthracyclines: The STOP-CA Trial

ACCEL Lite: Featured ACCEL Interviews on Exciting CV Research - Un podcast de American College of Cardiology - Les mardis

Catégories:

  Patients receiving chemotherapy regimens containing anthracyclines for lymphoma were significantly less likely to show evidence of heart dysfunction after taking atorvastatin for 12 months, according to research from the STOP-CA trial, a multicenter, randomized, double-blind, placebo-controlled study presented at ACC.23/WCC.  In this interview, Bonnie Ky MD, MSCE and Anthony N. DeMaria MD, MACC discuss “Statins To Prevent The Cardiotoxicity From Anthracyclines: The STOP-CA Trial.”  Subscribe on Apple Podcasts | Subscribe on Google Play | Subscribe to ACCEL  

Visit the podcast's native language site